Palbociclib exposure-response analyses in the treatment of hormone-receptor positive (HR plus ), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer (ABC)

被引：0
|
作者：
Zheng, Jenny
Yu, Yanke
Durairaj, Chandrasekar
Amantea, Michael
Dieras, Veronique
Finn, Richard
Wang, Diane
机构：
[1] Pfizer, San Diego, CA USA
[2] Inst Curie, Paris, France
[3] Ctr Eugene Marquis, Rennes, France
[4] Univ Calif Los Angeles, Geffen Sch Med, Santa Monica, CA USA
[5] Pfizer, Clin Pharmacol, San Diego, CA USA
来源：
CANCER RESEARCH | 2018年 / 78卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P5-21-21
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Palbociclib exposure-response analyses in second-line treatment of hormone-receptor positive advanced breast cancer (ABC).
    Sun, Wan
    Yu, Yanke
    Hoffman, Justin
    Turner, Nicholas C.
    Cristofanilli, Massimo
    Wang, Diane Dan
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [2] Hormone receptor positive (HR plus )/human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer: Sequencing of chemotherapy and endocrine therapy
    Engel-Nitz, Nicole M.
    Hao, Yanni
    Rogerio, Jaqueline Willemann
    Turnbull, James D.
    Rey, Gabriel Gomez
    Sullivan, Jane
    Rossof, Arthur H.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (26)
  • [3] Palbociclib Adherence and Persistence in Patients with Hormone Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer
    Engel-Nitz, Nicole M.
    Johnson, Mary G.
    Johnson, Michael P.
    Cha-Silva, Ashley S.
    Kurosky, Samantha K.
    Liu, Xianchen
    [J]. PATIENT PREFERENCE AND ADHERENCE, 2023, 17 : 1049 - 1062
  • [4] Overall survival (OS) with palbociclib plus fulvestrant in women with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Analyses from PALOMA-3
    Cristofanilli, M.
    Slamon, D. J.
    Ro, J.
    Bondarenko, I.
    Im, S-A.
    Masuda, N.
    Colleoni, M.
    DeMichele, A.
    Loi, S.
    Verma, S.
    Iwata, H.
    Harbeck, N.
    Loibl, S.
    Andre, F.
    Theall, K. Puyana
    Huang, X.
    Giorgetti, C.
    Bartlett, C. Huang
    Turner, N. C.
    [J]. ANNALS OF ONCOLOGY, 2018, 29
  • [5] Patients' preferences for postmenopausal hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer treatments in Japan
    Omori, Y.
    Enatsu, S.
    Cai, Z.
    Ishiguro, H.
    [J]. CANCER RESEARCH, 2019, 79 (04)
  • [6] Ribociclib (RIB) plus fulvestrant (FUL) in hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): MONALEESA-3 biomarker analyses
    Neven, P.
    Petrakova, K.
    Bianchi, G. V.
    Merino, L. De la Cruz
    Jerusalem, G.
    Beck, J. T.
    Sonke, G. S.
    Chia, S.
    Brucker, S.
    Wang, Y.
    He, W.
    Lorenc, K. Rodriguez
    Su, F.
    Im, S-A.
    [J]. ANNALS OF ONCOLOGY, 2018, 29 : 113 - +
  • [7] Real-world treatment duration of subsequent therapy after palbociclib (PAL) in patients with hormone receptor-positive (HR plus )/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) in Japan
    Sawaki, Masataka
    Muramatsu, Yasuaki
    Togo, Kanae
    Iwata, Hiroji
    [J]. CANCER RESEARCH, 2023, 83 (05)
  • [8] Overall survival (OS) with palbociclib (PAL) plus fulvestrant (FUL) in women with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Updated analyses from PALOMA-3.
    Cristofanilli, Massimo
    Rugo, Hope S.
    Im, Seock-Ah
    Slamon, Dennis J.
    Harbeck, Nadia
    Bondarenko, Igor
    Masuda, Norikazu
    Colleoni, Marco
    DeMichele, Angela
    Iwata, Sherene Loi Hiroji
    O'Leary, Ben
    Bananis, Eustratios
    Liu, Yuan
    Huang, Xin
    Kim, Sindy
    Lechuga, Mariajose
    Turner, Nicholas C.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [9] ECONOMIC ANALYSIS OF COMBINATION THERAPY WITH ALPELISIB AND FULVESTRANT FOR TREATMENT OF HORMONE RECEPTOR-POSITIVE (HR plus ) AND HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HER2-) ADVANCED BREAST CANCER
    Delevry, D.
    Le, Q. A.
    [J]. VALUE IN HEALTH, 2020, 23 : S32 - S33
  • [10] Ribociclib plus letrozole for first-line treatment of hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): efficacy by baseline tumor markers
    Andre, Fabrice
    Stemmer, Salomon M.
    Campone, Mario
    Petrakova, Katarina
    Paluch-Shimon, Shani
    Yap, Yoon-Sim
    Marschner, Norbert
    Chan, Arlene
    Villanueva, Cristian
    Hart, Lowell L.
    Arteaga, Carlos L.
    Sonke, Gabe S.
    Grischke, Eva-Maria
    Alba, Emilio
    Nusch, Arnd
    Yardley, Denise A.
    Jakobsen, Erik
    Blau, Sibel
    Tolaney, Sara M.
    Su, Faye
    He, Wei
    Germa, Caroline
    Hortobagyi, Gabriel N.
    [J]. CANCER RESEARCH, 2017, 77
12345